Phase 3 N=42 Statins in Children With Type 1 Diabetes and Hypercholesterolemia
Diabetes Mellitus, Insulin-Dependent · Hypercholesterolemia
Primary: LDL-C Levels Assessed at Randomization and 6 Months — 128; 87; 126; 133 mg/dL — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Improving Health Communication During the Transition From Pediatric to Adult Diabetes Care
Type 1 Diabetes Mellitus
Primary: Hemoglobin A1c — 7.988; 8.025 A1c percentage
N/A N=208 Transdisciplinary Versus Usual Care for Type1 Diabetes in Adolescence
Type 1 Diabetes Mellitus
Primary: Glycosylated Hemoglobin (HbA1c) — 8.59; 9.02; 8.71; 9.03 percentage of glycosylated hemoglobin — p=0.895
Phase 1 N=30 A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy
Diabetes Mellitus, Type 1
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve From Time Zero to 5 Hours (AUC[0-5h]) (Part A) — 719; 783 picomole*hour per liter (pmol*h/L)
N/A N=96,759 Impact of Medicaid Health Home on Patients With Diabetes in New York City
Type 2 Diabetes Mellitus
Primary: Number of Enrollees With Diabetes-related Preventable Hospitalizations — 48; 109; 48; 90 Participants
N/A N=34 Effect of Whole Fruit on Glycemic Control in Adults With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Diabetes Remission Rate — 3; 6 Participants — p=<0.0001
Phase 2 N=62 Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Primary: Part 1: Selected Part 2 Dose of Risdiplam — 0.2 mg/kg
N/A N=79 Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients
Diabetes Mellitus, Type 2
Primary: Self-Care Activities: Healthy Eating — 4.23; 4.67; 4.61; 4.60 days/week (min: 0 days; Max: 7 days)
Phase 2 N=29 The Effects of Potassium on Glucose Metabolism in African Americans
Borderline Hypokalemia
Primary: Change in Glucose Tolerance as Measured by Area-under-the-curve — 328; 1000 AUC - mg*min/dL — p=0.5582
Phase 3 N=28 Adjunctive Metformin Therapy in Double Diabetes
Diabetes Mellitus
Primary: Baseline Adjusted Hemoglobin A1c Over Time — 9.46; 9.85 percentage of HbA1c — p=0.903
N/A N=214 Tailored Diabetes Self-Management Resources
Diabetes Mellitus, Type 1
Primary: Change in Hemoglobin A1c for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention — 0.014; 0.018; 0.035; 0.025 Percent HbA1c per month…
N/A N=225 Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes
Diabetes Mellitus
Primary: Decisional Conflict in Patients With Diabetes — 25.53; 23.56; 21.97; 21.10 score on a scale — p=0.0246
N/A N=218 Veteran Support and Resources for Diabetes
Diabetes
Primary: Change in Diabetes Distress Screening Scale (DDS17) — 3.0; 3.1; 3.3; 3.3 score on a scale — p=0.42
Phase 2 N=114 New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
Diabetes Mellitus, Type 1
Primary: Mean Stimulated C-peptide Area Under the Curve — 0.28; 0.27; 0.25 pmol/ml — p=0.47
N/A N=120 Differing Completion Rates of DIABETES Education on Patient Reported Outcomes
Diabetes Mellitus, Type 2 · Patient Education as Topic
Primary: Change in DSMQ Diabetes Self Management Questionnaire Measuring Diabetes Self Management Skills Pre and Post Intervention — .96; 1.08; .28; -.17 change score (difference…